Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 2.27B |
| Revenue (ttm) | 70.79M |
| Net Income (ttm) | -268.64M |
| Shares Out | 93.09M |
| EPS (ttm) | -3.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,619,744 |
| Open | 23.26 |
| Previous Close | 22.55 |
| Day's Range | 22.33 - 24.83 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 39.20 (+60.52%) |
| Earnings Date | Nov 5, 2025 |
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e... [Read more]
Financial Performance
In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price target is $39.2, which is an increase of 60.52% from the latest price.
News
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for ser...
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for ser...
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Announces Proposed Underwritten Public Offering
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for seri...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease
Viridian Therapeutics (VRDN) offers a differentiated next-gen therapy for Thyroid Eye Disease, targeting a large, underpenetrated market dominated by Amgen's Tepezza. VRDN-001 (veligrotug) demonstrate...
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains...
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing...
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to T...
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved th...
Viridian Therapeutics' eye disorder drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.